Fremanezumab does not raise CV concerns, even in high-risk migraine patients
Patients using the CGRP* blocker fremanezumab for migraine treatment need not worry about cardiovascular (CV) safety of the drug, as pooled data from three phase III trials showed no safety signals for CV events with the treatment, even in those with a CV medical history.
Fremanezumab does not raise CV concerns, even in high-risk migraine patients
04 Jun 2020
